ReviewDrugs2016
Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- [Diagnostics and treatment of type 1 diabetes mellitus (Update 2026)].Wiener klinische Wochenschrift · 2026Guideline
- Trial
- Pharmacokinetics, Pharmacodynamics, and Bioequivalence of Test Insulin Glargine Versus Reference Preparation (LantusPharmaceutics · 2025Article
- New therapies towards a better glycemic control in youths with type 1 diabetes.Pharmacological research · 2023Review
- [Injection therapy of diabetes].Wiener klinische Wochenschrift · 2023Article
- [Diagnosis and insulin therapy of type 1 diabetes mellitus (Update 2023)].Wiener klinische Wochenschrift · 2023Article
- Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300).BMJ open diabetes research & care · 2022Review
- Case Report: High-concentration Insulin Glargine Overdose Complicated by Hepatic Steatosis.Journal of the Endocrine Society · 2020Article
- Article
- [Diagnosis and insulin therapy of type 1 diabetes mellitus (Update 2019)].Wiener klinische Wochenschrift · 2019Review
- [Insulin therapy of type 2 diabetes mellitus (Update 2019)].Wiener klinische Wochenschrift · 2019Review
- Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.Journal of diabetes research · 2018Review
- Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.Clinical pharmacokinetics · 2017Review
- Basal insulin regime change from Lantus to Toujeo resulted in fewer hypoglycaemic episodes in a 28-year-old man with diabetes mellitus.BMJ case reports · 2016Article
- Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives.Patient preference and adherence · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin glargine 300 U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity exceeding 24 h. In several 6-month phase III trials, insulin glargine 300 U/mL achieved comparable glycaemic control to that seen with insulin glargine 100 U/mL in patients with type 1 or type 2 diabetes, albeit with consistently higher daily basal insulin requirements. These improvements in glycaemic control were maintained during longer-term (12 months) treatment. Insulin glargine 300 U/mL was generally associated with a lower risk of nocturnal hypoglycaemia than insulin glargine 100 U/mL in insulin-experienced patients with type 2 diabetes, while the risk of nocturnal hypoglycaemia did not significantly differ between treatment groups in insulin-naïve patients with type 2 diabetes or in patients with type 1 diabetes. To conclude, once-daily subcutaneous insulin glargine 300 U/mL is an effective and generally well tolerated basal insulin therapy option for patients with type 1 or type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.